Investigational Drug Information for Imexon
✉ Email this page to a colleague
What is the drug development status for Imexon?
Imexon is an investigational drug.
There have been 8 clinical trials for Imexon.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2008.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Waldenstrom Macroglobulinemia, and Lung Neoplasms. The leading clinical trial sponsors are AmpliMed Corporation, University of Rochester, and University of Arizona.
Summary for Imexon
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 181 |
| WIPO Patent Applications | 142 |
| Japanese Patent Applications | 52 |
| Clinical Trial Progress | Phase 2 (2008-04-01) |
| Vendors | 18 |
Recent Clinical Trials for Imexon
| Title | Sponsor | Phase |
|---|---|---|
| Imexon for Relapsed Follicular and Aggressive Lymphomas | University of Arizona | Phase 2 |
| Imexon for Relapsed Follicular and Aggressive Lymphomas | University of Rochester | Phase 2 |
| A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer | AmpliMed Corporation | Phase 2 |
Clinical Trial Summary for Imexon
Top disease conditions for Imexon
Top clinical trial sponsors for Imexon
US Patents for Imexon
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
